BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma

Human Pathology

Volumn 45, Issue 10, 2014, Pages 2144-2153

  Kendrick, Samantha L ^a   Redd, Lucas ^a   Muranyi, Andrea ^b   Henricksen, Leigh A ^b   Stanislaw, Stacey ^b   Smith, Lynette M ^c   Perry, Anamarija M ^d   Fu, Kai ^e   Weisenburger, Dennis D ^f   Rosenwald, Andreas ^g   Ott, German ^h   Gascoyne, Randy D ⁱ   Jaffe, Elaine S ^j   Campo, Elías ^k   Delabie, Jan ^l   Braziel, Rita M ^m   Cook, James R ⁿ   Tubbs, Raymond R ⁿ   Staudt, Louis M ^j   Chan, Wing Chung ⁱ   Steidl, Christian ⁱ   Grogan, Thomas M ^a,b   Rimsza, Lisa M ^a   more..

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF MANITOBA   (Canada)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF WÜRZBURG   (Germany)

^h ROBERT BOSCH HOSPITAL   (Germany)

ⁱ BRITISH COLUMBIA CANCER AGENCY   (Canada)

^j NATIONAL CANCER INSTITUTE   (United States)

^k HOSPITAL CLÍNIC   (Spain)

^l UNIVERSITY OF OSLO   (Norway)

^m OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁿ LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

BCL2 amplification and translocation; BCL2 phosphorylation; Diffuse large B cell lymphoma; Dual in situ hybridization (dual ISH); E17 and SP66 BCL2 antibodies

Indexed keywords

EPITOPE; FORMALDEHYDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E17; MONOCLONAL ANTIBODY SP66; MYC PROTEIN; PARAFFIN; PROTEIN BCL 2; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; CANCER SURVIVAL; CANCER TISSUE; CLONE; COHORT ANALYSIS; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANIMAL; DIAGNOSTIC USE; GENETICS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METABOLISM; PROCEDURES; RABBIT; TISSUE MICROARRAY;

ANIMALS; ANTIBODIES, MONOCLONAL; EPITOPES, B-LYMPHOCYTE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROTO-ONCOGENE PROTEINS C-BCL-2; RABBITS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84908159321     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2014.06.005     Document Type: Article

References (27)

1. J. Iqbal, P.N. Meyer, and L. Smith BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and Rituximab Clin Cancer Res 17 2011 7785 7795
2. J. Iqbal, V.T. Neppalli, and G. Wright BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma J Clin Oncol 24 2006 961 968
3. M.P. Jovanovic, L. Jakovic, A. Bogdanovic, O. Markovic, V.C. Martinovic, and B. Mihaljevic Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells Vojnosanit Pregl 66 2009 738 743
4. J.G. Lohr, P. Stojanov, and M.S. Lawrence Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing Proc Natl Acad Sci U S A 109 2012 3879 3884
5. N.A. Johnson, G.W. Slack, and K.J. Savage Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone J Clin Oncol 30 2012 3452 3459
6. A.M. Perry, Y. Alvarado-Bernal, and J.A. Laurini MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab Br J Haematol 165 2014 382 391
7. B.F. Skinnider, D.E. Horsman, B. Dupuis, and R.D. Gascoyne Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities Hum Pathol 30 1999 803 808
8. J.Z. Huang, W.G. Sanger, and T.C. Greiner The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile Blood 99 2002 2285 2290
9. J. Iqbal, W.G. Sanger, and D.E. Horsman BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma Am J Pathol 165 2004 159 166
10. J. Dierlamm, E.M. Murga Penas, and S. Bentink Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL-2 gene dosage and protein expression in diffuse large B-cell lymphoma Haematologica 93 2008 688 696
11. S. Bea, A. Zettl, and G. Wright Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction Blood 106 2005 3183 3190
12. S.L. Barrans, I. Carter, and R.G. Owen Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma Blood 99 2002 1136 1143
13. G. Lenz, G.W. Wright, and N.C. Emre Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways Proc Natl Acad Sci U S A 105 2008 13520 13525
14. O. Bairey, Y. Zimra, M. Shaklai, E. Okon, and E. Rabizadeh Bcl-2, Bcl-2X, Bax, and Bak expression in short-and long-lived patients with diffuse large B-cell lymphomas Clin Cancer Res 5 1999 2860 2866
15. M. Schraders, D. de Jong, P. Kluin, P. Groenen, and H. van Krieken Lack of Bcl-2 epxression in follicular lymphoma may be casued by mutations in the BCL2 gene or by absence of the t(14;18) translocation J Pathol 205 2005 329 335
16. P. Adam, R. Baumann, and J. Schmidt The BCL2 E17 and SP66 antibodies discriminate 2 immunophenotypically and genetically distinct subgroups of conventionally BCL2-"negative" grade 1/2 follicular lymphomas Hum Pathol 44 2013 1817 1826
17. N. Masir, L.J. Campbell, M. Jones, and D.Y. Mason Pseudonegative BCL2 protein expression in a t(14;18) translocation positive lymphoma cell line: a need for an alternative BCL2 antibody Pathology 42 2010 212 216
18. J.M. Schuetz, N.A. Johnson, and R.D. Morin BCL2 mutations in diffuse large B-cell lymphoma Leukemia 26 2012 1383 1390
19. A. Rosenwald, G. Wright, and W.C. Chan The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma N Engl J Med 346 2002 1937 1947
20. P.N. Meyer, K. Fu, and T.C. Greiner Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab J Clin Oncol 29 2011 200 207
21. H. Nitta, B. Hauss-Wegrzyniak, and M. Lehrkamp Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH) Diagn Pathol 3 2008 41
22. H. Nitta, W. Zhang, and B.D. Kelly Automated brightfield break-apart in situ hybridization (ba-ISH) application: ALK and MALT1 genes as models Methods 52 2010 352 358
23. C. Valentino, S. Kendrick, and N. Johnson Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma Am J Clin Pathol 139 2013 242 254
24. C. Stasik, H. Nitta, and W. Zhang Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma Hematologica 95 2010 597 603
25. T. Ito, X. Deng, B. Carr, and W.S. May Bcl-2 phosphorylation required for anti-apoptosis function J Biol Chem 272 1997 11671 11673
26. X. Deng, F. Gao, T. Flagg, J. Anderson, and W.S. May Bcl2's flexible loop domain regulates p53 binding and survival Mol Cell Biol 26 2006 4421 4434
27. D. de Jong, A. Rosenwald, and M. Chhanabhai Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications - a study from the Lunenburg Lymphoma Biomarker Consortium J Clin Oncol 25 2007 805 812